CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Model scores of the 29,894 trials active now.

Model score 71% for any early termination, 37% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 30% of the time (96 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-01-17. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: or equalequal togreater thanventricularpatients must
  Phrases that lowered it: smokingwith typesafetyhistorymodifying
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 12.3% (raises risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 286 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 28.9% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 96.9% (raises risk) · Drug's FDA history
• Maximum age: 70 (lowers risk) · Who can join
• Sponsor type: government (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Design: sequential (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 NCT01082926 · started 2010 · scored riskier than 44% of active trials completed
• Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma NCT02209376 · started 2014 · scored riskier than 99% of active trials terminated
• A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas NCT01130077 · started 2009 · scored riskier than 70% of active trials completed
• Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM NCT03283631 · started 2018 · scored riskier than 83% of active trials terminated
• Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma NCT01582516 · started 2010 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.